anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an acanthamoeba specific antigen peptide, a polyclonal antibody and application thereof, wherein the amino acid sequence of the specific antigen peptide is shown as SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7 or SEQ ID NO. 9. The invention carries out immunological screening on the acanthamoeba trophosome full-length cDNA library by using acanthamoeba infected rabbit serum to obtain an antigen gene with high reactogenicity, further carries out prokaryotic expression and immunogenicity identification on the screened antigen gene, and the screened antigen peptide immunized animal can show the levels of local specificity SIgA, IgG and IgA and has effective anti-infection protection performance on experimental animals, and the antigen peptide has important significance for preventing acanthamoeba keratitis of animals and human beings. Meanwhile, the polyclonal antibody prepared by the antigen peptide immune animal has the characteristics of strong specificity and high purity, and can be used for clinical diagnosis of acanthamoeba keratitis. The antigenic peptide provided by the invention can be used for preparing a medicine for preventing or treating acanthamoeba keratitis.
Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15, and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Copanlisib will be given at 30mg, 45mg, or 60 mg depending on the assigned dose level. Venetoclax will have a weekly dose ramp up from 20mg, 50mg, 100mg, 200mg, and then 400mg thereafter.
This is a Phase II trial of NEOADJUVANT FOLFIRINOX CHEMOTHERAPY WITH PEMBROLIZUMAB followed by SURGERY and Adjuvant PEMBROLIZUMAB for Patients with LOCALIZED, RESECTABLE Adenocarcinoma of the pancreas. Investigators hypothesize that appropriately timed neoadjuvant FOLFIRINOX with anti-PD-1 mAb (pembrolizumab) can be administered safely and feasibly, and that this combination will lead to improved clinical response associated with enhanced numbers of immune cells in surgically resected pancreatic tumors. Patients will receive 6 cycles of FOLFIRINOX with 2 cycles of PEMBROLIZUMAB before surgical resection. Following surgery patients will receive 5FU based chemotherapy for up to 6 cycles with 7 more cycles of PEMBROLIZUMAB. Patients will receive a total of 9 doses of Q6week cycles of PEMBROLIZUMAB.

Toxicities will be continuously monitored using the method proposed by Ivanova et al. \[Ivanova, A., Qaqish, B.F., and Schell, M.J. (2005). Continuous toxicity monitoring in phase II trials in oncology. Biometrics 61: 540-545.\]. The method generates a Pocock-type stopping boundary for repeated testing for toxicity. Sequential boundaries will be used to monitor dose-limiting toxicity rate. The accrual will be halted if excessive numbers of dose-limiting toxicities are seen, that is, if the number of dose-limiting toxicities is equal to or exceeds boundary number out of the number of patients with full follow-up. This is a Pocock-type stopping boundary that yields the probability of crossing the boundary at most 5% when the rate of dose-limiting toxicity is equal to the acceptable rate of 25%.
HYZAAR contains 2 prescription medicines, an angiotensin receptor blocker (ARB) and a diuretic (water pill). It is used to: 

  * lower high blood pressure (hypertension). HYZAAR is not usually the first medicine used to treat high blood pressure. 
  * lower the chance of stroke in patients with high blood pressure and a heart problem called left ventricular hypertrophy (LVH). HYZAAR may not help Black patients with this problem. 



HYZAAR has not been studied in children less than 18 years old.

High Blood Pressure (hypertension). Blood pressure is the force in your blood vessels when your heart beats and when your heart rests. You have high blood pressure when the force is too much. The losartan ingredient in HYZAAR can help your blood vessels relax so your blood pressure is lower. The hydrochlorothiazide ingredient in HYZAAR works by making your kidneys pass more water and salt.

Left Ventricular Hypertrophy (LVH) is an enlargement of the walls of the left chamber of the heart (the heart's main pumping chamber). LVH can happen from several things. High blood pressure is the most common cause of LVH.
Compositions and methods for making and using proliposomes and liposomal formulations of chemotherapeutic agents are disclosed. Proliposome and liposome formulations of chemotherapeutic agents, as well as medicaments and dosage forms comprising such formulations, may be used with treatment regimens for bladder cancer and urothelial cancer. Thus, the formulations, medicaments and dosage forms of the invention are suitable for the treatment of bladder cancer and for the treatment of urothelial cancer by intravesical administration. The formulations according to the invention comprise (a) a taxane (e.g. paclitaxel, docetaxel) or cisplatin, (b) a first phospholipid, Dipalmitoylphosphatidylcholine (DMPC) and (c) a second phospholipid, dimyristoylphosphatidylglycerol sodium (DMPG). The proliposomal formulation forms liposomes when contacted with an aqueous carrier.
<P>PROBLEM TO BE SOLVED: To prepare a sheet-like pack cosmetic having excellent beauty effect even when the amount of the cosmetic is small, a packed cosmetic in which the cosmetic components are made permeable into skin, and a packed cosmetic having a large degree of prescription freedom.  <P>SOLUTION: A support base material is impregnated or coated with cosmetic agents, then metal foil or a laminate material containing metal foil is laminated on the cosmetic support base material to prepare a sheet-like packed cosmetic. The support base material is preferably nonwoven fabric. Since the sheet-like packed cosmetic according to this invention is laminated on one face with the metal foil, the laminate material containing metal foil or a ceramic evaporated layer, there is no case where the components in the cosmetic vaporize in the air while it is used and the cosmetic components easily migrates into skin and sufficient beauty effect can be expected with small amounts of components. The problems on the dripping of a cosmetic solution, or the like, can be minimized. In addition, the cosmetic can be freely applied independently from the prescription of the cosmetic agents and the degree of freeness of the formulation can be expanded.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The estimated radiation absorbed doses for adults from intravenous injection of Neuraceq are shown in Table 1.

The effective dose resulting from a 300 MBq (8.1 mCi) administration of Neuraceq in adult subjects is 5.8 mSv. The use of a CT scan to calculate attenuation correction for reconstruction of Neuraceq images (as done in PET/CT imaging) will add radiation exposure. Diagnostic head CT scans using helical scanners administer an average of 2.2 mSv ± 1.3 mSv effective dose (CRCPD Publication E-07-2, 2007). The actual radiation dose is operator and scanner dependent. Thus, the total combined radiation exposure from Neuraceq administration and subsequent scan on a PET/CT scanner is estimated to be 8 mSv.
The ARAMIS Registry is a multicenter, cohort study of patients presenting with acute ischemic stroke (AIS) or intracerebral hemorrhage (ICH) while taking chronic anticoagulation therapy. The goals of ARAMIS are to (1) examine the prevalence of preadmission novel oral anticoagulants use among patients with AIS or ICH; (2) describe and characterize coagulation tests being used to assess the level of anticoagulation in these patients; (3) examine the utilization and safety profile of thrombolytic therapy in AIS patients taking new classes of anticoagulants; and (4) document treatment patterns of anticoagulation-related ICH and compare how care and outcomes vary by novel oral anticoagulants and warfarin. The acquisition of such findings will be of critical importance to help fill in gaps on guideline recommendations and provide insights into the management of AIS and ICH patients on treatment with new anticoagulants. This will allow physicians to feel more confident in anticoagulation therapy while improving the care and outcomes of patients on these agents who have stroke complications.

The ARAMIS builds upon the backbone of the nation's largest ongoing stroke registry, Get With The Guidelines-Stroke (GWTG-Stroke) by the American Heart Association/American Stroke Association (AHA/ASA). The GWTG-Stroke registry provides data on patient demographics, medical history, laboratory results, brain imaging, in-hospital treatment and outcomes. Using this existing resource, ARAMIS will create a new on-line supplemental data collection module and specifically collect information on medications prior to admission, diagnostic testing, treatment, factors associated with treatment decision making as well as clinical outcomes. A total of 10,000 consecutive patients 18 years or older, who experience an AIS (n=5,000) while taking a novel oral anticoagulant (dabigatran, rivaroxaban, apixaban, or edoxaban) or have an ICH (n=5,000) while taking warfarin or one of the novel oral anticoagulants within 7 days prior to the stroke onset will be enrolled in approximately 3-4 years. Beyond the index hospitalization, ARAMIS will enroll 2500 consecutive patients (1250 AIS and 1250 ICH) who survive and provide informed consent at discharge for the follow-up study. Trained personnel from the Duke Clinical Research Institute (DCRI) Call Center will conduct structured telephone interviews with these patients at 3 and 6 months following their index hospitalization. The follow-up interview will extend the baseline data collection at GWTG-Stroke and ARAMIS and include long-term medication, downstream care, and patient-reported outcomes, Obtaining such information will not only provide a longitudinal perspective on care and outcomes, but will also allow for innovative patient-centered outcomes and comparative effective research.
Participants in the LUMEEN intervention group will participate in the 12 LUMEEN Virtual Reality sessions of 45 minutes taking place twice a week for 6 weeks, in groups of 6 participants. The content of these sessions is described in the Intervention Description part of this document.
Novel retroviral vectors were constructed by making modifications to the Moloney murine leukemia virus (MoMLV) long terminal repeat (LTR). A portion of the U3 region of the MoMLV LTR was replaced with a hybrid regulatory element consisting of the human cytomegalovirus immediate-early enhancer/promoter (CMV-IE) together with the human immunodeficiency virus transactivation response element (HIV-TAR). Transfection of chloramphenicol acetyl transferase (CAT) reporter constructs into a variety of human cell lines showed that the CMV-IE/HIV-TAR enhancer/promoter chimeric MoMLV LTR exhibited basal expression levels which were 10- to 50-fold higher than those obtained from the wild-type MoMLV LTR enhancer/promoter. Expression from the recombinant LTR was further increased in the presence of the HIV-1 Tat protein. When stably transfected into an amphotropic packaging cell line, the modified retroviral vector containing the chimeric LTR plus an extended packaging signal consistantly gave higher titers of retrovirus than did the parental MoMLV based vector. These novel retroviral vectors provide improved means for the delivery and expression of genes in different cell types.
The present invention relates to a functional cosmetic composition which is for ameliorating atopic dermatitis and helps ameliorate atopic dermatitis on the basis of natural ingredients. The present invention provides a cosmetic composition for ameliorating atopic dermatitis, the composition containing a plurality of natural ingredients, bases, and additives. The natural ingredients include Cicada slough, Angelica Dahurica, Scutellariae Radix, Angelica sinensis, Coptidis Rhizoma, Phellodendri Cortex, Rehmanniae Radix Recens, Gardeniae Fructus, Cnidii Rhizoma, Paeonia lactiflora Pallas, Saposhnikoviae Radix, and Glycyrrhiza uralensis. The bases include a water base and an oil base. The water base includes at least one among a grape seed extract, an olive leaf extract, a jojoba seed extract, an evening primrose extract, and a Scutellariae Radix extract. The oil base includes at least one among evening primrose oil, jojoba oil, emu oil, olive oil, grape seed oil, coconut oil, avocado oil, Zanthoxyli Pericarpium oil, camellia seed oil, evening primrose seed oil, hemp seed oil, and flaxseed oil. The additives include hyaluronic acid and propolis.
<P>PROBLEM TO BE SOLVED: To provide a constipation improving food easily ingestible and bringing about expecting effect with small amount.  <P>SOLUTION: A method for producing the constipation improving food comprises extracting intercellular mucopolysaccharide from marine algae obtained by mixing brown algae and red algae with green algae in hot water, and subjecting the marine algae from which the intercellular mucopolysaccharide is extracted in hot water to enzymatic hydrolysis to obtain marine alga enzymolytic liquid. The group of conjugated enzyme used for enzymatic hydrolysis consists of cellulase, pectinase, alginate lyase, carragenase and protease. Furthermore, the method comprises adding water soluble dietary fiber and oligosaccharide to the marine alga enzymolytic liquid, and processing the food into powder, granules or pills so as to make the food excellent in portability and easy to ingest. The food brings definite constipation improving effect even through ingestion with small amount. As any of the marine algae is a traditional food, it is safe as a food.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
FIELD: medicine. SUBSTANCE: method involves administering Polyphepan sorbent agent beginning from the first treatment day. Low frequency therapy is applied to liver or spleen area in daily mode. Polyphepan is administered for 6-8 days. Then baths having standardized composite of biologically active substances like Tonus+P daily, 12-14 procedures per course. Low frequency magnetic therapy is applied during the whole treatment course with magnetic induction value being increased every 3-4 procedures from 10 mTesla units to 30 mTesla units and exposure time being increased 15-320 min long. The total treatment course is 10-11 procedures long and applied to each treatment area. EFFECT: enhanced effectiveness of immunity correction effect. 7 tbl _
When treating posterior crossbite, the primary goal is to achieve long-term crossbite correction. The majority of studies however focus on relapse of the increase in the transverse dimension, but not relapse of the crossbite itself, which is an essential outcome. The aim of the present study was to determine long-term stability (2 years minimum post-treatment) of posterior crossbite correction, treated in mixed or early permanent dentitions of growing children. Following registration in PROSPERO (CRD42022348858), an electronic literature search including PubMed, Embase, Web of Science, the Cochrane Library, and a manual search were conducted up to January 2023, to identify longitudinal studies looking into the long-term stability of crossbite correction in growing children. Data extraction and risk of bias assessment were carried out, and subsequently, a random-effects meta-analyses models were used to calculate estimates for relapse of the crossbite and relapse at the transverse level. Twenty-two studies were included, of varying designs and quality, representing 1076 treated patients, with different expansion appliances and protocols. Meta-analysis results showed that 19.5% (95% CI: 15%; 25%) of patients present with relapse of posterior crossbite at long-term follow-up. At the transverse level, 19.3% of the total expansion (including overexpansion) relapsed (95% CI: 13%; 27%) regardless of whether there a was relapse of the crossbite itself. Data from existing studies, with a moderate level of evidence, indicate that the long-term stability of posterior crossbite correction in growing children is unfavourable in roughly 1 in 5 growing children, with crossbite relapse long-term. On average, 19% of the maxillary expansion performed (including overexpansion) relapses long-term, which may occur in cases with or without relapse of the crossbite.
Participants will complete their virtual reality (VR) visual training program from their own homes using a head-mounted display (HMD) that is on loan for the study. Participants will receive initial training on using the device and software at the clinic and will take home the HMD to complete their 6-weeks of visual training independently from home. Additional training and FAQ materials will be given to participants to use as reference.
The invention discloses a preparation method of iodine-labeled gelatin microspheres with a high labeling rate. With the method, novel iodine-labeled gelatin microspheres are obtained. According to the invention, 2,3-dihydroxybenzoic acid (DHBA) is introduced into gelatin microspheres; the novel-structured gelatin microspheres are subjected to radioiodine labeling, such that the iodine-labeled modified gelatin microspheres are obtained, and the labeling rate reaches 64% (the radioiodine labeling rate of non-modified gelatin microspheres is only 20%). With the method, the labeling rate of the radioiodine-labeled gelatin microspheres is greatly improved, and the high-labeling iodine-labeled gelatin microspheres have good biocompatibility and biodegradability. The radioiodine-labeled microspheres can be used for treating cancers. The structure of the modified gelatin microspheres is shown in the descriptive drawings.
The various embodiments herein provide a gel based wound dressing comprising a lyophilized powder and a water-based solvent. The lyophilized powder comprises several nanoparticles and water miscible natural or synthetic polymers. The nanoparticles comprises pectin and a wound healing agent or an anti-microbial agent. The anti-microbial agent is nisin. The lyophilized powder and the water-based solvent are kept in two separate sealed packages and are mixed together before applying on a wound. The embodiments herein also provide a method of synthesizing the gel based wound dressing. The nano-particles control a release of the wound healing agent or the antimicrobial agent to a wound.
In this study, the investigators will conduct a decentralized, remote, eight-week, two-arm, randomized controlled trial of SynerGI, a disease-targeted, brain-gut directed, immersive VR program for people with IBS, versus sham VR delivered in a VR headset. Eligible participants will be assigned to a study arm using a 1:1 random number generator and will be blinded to allocation. Data analysts will also be blinded to allocation; only pre-specified staff who are uninvolved with data analyses will be unblinded for purposes of study administration (e.g., sending allocation-specific study materials). After completion of the treatment, participants will be invited to participate in an optional 30-minute semi-structured interview to better understand their experiences of VR treatment. Qualitative interviews will be audio-recorded and transcribed.

The primary aim of this study will be to assess the benefits of disease-targeted VR compared to sham VR on clinically relevant outcomes. The second aim will seek to determine patient-level predictors of treatment response to active VR therapy. The third aim will seek to understand patient experiences of VR to better inform the design of VR treatments for digestive diseases in the future.
The invention belongs to a chicken coccocidiosis preventing and treating composition in veterinary drugs. The chicken coccocidiosis preventing and treating composition is composed of the effective component by weight: 80% of xytetracycline hydrochloride and 20% of trimethoprem. The veterinary drug composition is used for treating the coccocidiosis and the bacterial diseases of chicken, and the cure rate is above 96%. The process for processing the composition comprises accurately weighing all of the effective components dried previously, mixing, weighing and packaging, testing quality and warehousing. The method of using the composition comprises mixing the composition with other materials by the proportion of 0.05-0.1%. The composition is applied continuously for 3-5 days as a course of treatment.
Hepatitis B virus (HBV) damages liver cells through abnormal immune responses. Mitochondrial metabolism is necessary for effector functions of white blood cells (WBCs). The aim was to investigate the altered counts and mitochondrial mass (MM) of WBCs by two novel indicators of mitochondrial mass, MM and percentage of low mitochondrial membrane potential, MMPlow%, due to chronic HBV infection. The counts of lymphocytes, neutrophils and monocytes in the HBV infection group were in decline, especially for lymphocyte (p = 0.034) and monocyte counts (p = 0.003). The degraded MM (p = 0.003) and MMPlow% (p = 0.002) of lymphocytes and MM (p = 0.005) of monocytes suggested mitochondrial dysfunction of WBCs. HBV DNA within WBCs showed an extensive effect on mitochondria metabolic potential of lymphocytes, neutrophils and monocytes indicated by MM; hepatitis B e antigen was associated with instant mitochondrial energy supply indicated by MMPlow% of neutrophils; hepatitis B surface antigen, antiviral therapy by nucleos(t)ide analogues and prolonged infection were also vital factors contributing to WBC alterations. Moreover, degraded neutrophils and monocytes could be used to monitor immune responses reflecting chronic liver fibrosis and inflammatory damage. In conclusion, MM combined with cell counts of WBCs could profoundly reflect WBC alterations for monitoring chronic HBV infection. Moreover, HBV DNA within WBCs may be a vital factor in injuring mitochondria metabolic potential.
Matrine (MT) has shown promising efficacy in various cancers and chronic hepatitis; however, its clinical application is limited because of its side effects. Our previous studies have indicated that MT can induce severe hepatotoxicity and nephrotoxicity. The current study aimed to investigate its cardiotoxicity and potential underlying mechanisms in H9c2 cells. Our results showed that MT induced H9c2 cell death and disrupted the cellular membrane integrity. Moreover, MT decreased glutathione (GSH) and cysteine (Cys) levels, and increased Fe2+, lipid peroxidation, reactive oxygen species (ROS), and MDA levels, ultimately leading to ferroptosis. Interestingly, these phenomena were alleviated by the ferroptosis inhibitor Fer-1, whereas MT-induced ferroptosis was exacerbated by the ferroptosis agonist RSL3. In addition, MT significantly reduced FTH, Nrf2, xCT, GPX4, and FSP1 protein levels and inhibited the transcriptional activity of Nrf2 while increasing TFR1 protein levels. Supplementation with Nrf2 agonist (Dimethyl fumarate, DMF) or selenium (Sodium selenite, SS) and CoQ10 alleviated MT-induced cytotoxic effects in H9c2 cells. These results suggest that ferroptosis, which is mediated by an imbalance in the Nrf2 antioxidant system, is involved in MT-induced cardiac toxicity.